GamEvac-Combi explained
| Drug Name: | GamEvac-Combi |
| Type: | vaccine |
| Target: | Ebola |
| Vaccine Type: | heterologous |
| Legal Status: | Registered (Russia) |
GamEvac-Combi (Russian: ГамЭвак-Комби) is a heterologous VSV- and Ad5-vectored Ebola vaccine. There is also a version called GamEvac which is a homologous Ad5-vectored vaccine.[1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology. the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.
Description
The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.[2] The vaccine is targeted against the Makona variant of Ebola that was circulating in West Africa during the 2013-2016 outbreak.[3]
History
GamEvac-Combi was licensed by the Ministry of Health of the Russian Federation for emergency use in the territory of the Russian Federation in December 2015. The emergency license was based on Phase I and II clinical data of safety and immunogenicity.[4]
See also
Notes and References
- Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, Syromyatnikova SI, Borisevich SV, Pantyukhov VB, Babira VF, Kolobukhina LV, Naroditsky BS, Logunov DY, Gintsburg AL . 6 . Virus-Vectored Ebola Vaccines . Acta Naturae . 9 . 3 . 4–11 . 2017 . 29104771 . 5662269 . 10.32607/20758251-2017-9-3-4-11 .
- Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Tokarskaya EA, Simakova YV, Egorova DA, Scherbinin DN, Tutykhina IL, Lysenko AA, Kostarnoy AV, Gancheva PG, Ozharovskaya TA, Belugin BV, Kolobukhina LV, Pantyukhov VB, Syromyatnikova SI, Shatokhina IV, Sizikova TV, Rumyantseva IG, Andrus AF, Boyarskaya NV, Voytyuk AN, Babira VF, Volchikhina SV, Kutaev DA, Bel'skih AN, Zhdanov KV, Zakharenko SM, Borisevich SV, Logunov DY, Naroditsky BS, Gintsburg AL . 6 . Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia . Human Vaccines & Immunotherapeutics . 13 . 3 . 613–620 . March 2017 . 28152326 . 5360131 . 10.1080/21645515.2016.1238535 .
- Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J . Ebola virus disease . Lancet . 393 . 10174 . 936–948 . March 2019 . 30777297 . 10.1016/s0140-6736(18)33132-5 . free .
- Web site: Update with the development of Ebola vaccines and implications of emerging evidence to inform future policy recommendations . . 14 August 2020.
